HARNESSING DC SUBSETS FOR IMPROVED MUCOSAL IMMUNITY

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 这是一项比较疫苗研究，旨在测试哪种DC靶向载体可以诱导对流感感染最有效的保护性免疫。抗体介导的免疫是预防流感感染的重要免疫臂。为了评估注射给药的DC靶向疫苗的效力，我们使用了当前的疫苗Fluzone作为阳性对照。虽然这项研究的主要目的是测试HA1特异性体液反应，但我们也将测试HA1特异性细胞反应的大小和光谱，这是激发强大的体液免疫所必需的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This is a comparative vaccine study to test which DC-targeting vehicle can elicit the most potent protective immunity against influenza infection. Antibody-mediated immunity is an important immune arm for the prevention of influenza infection. To evaluate the potency of DC-targeting vaccines administered i.d., we employ a current vaccine, Fluzone, as a positive control. Although the main objective of this study is to test HA1-specific humoral responses, we will also test the magnitude and spectrum of HA1-specific cellular responses that are necessary for eliciting potent humoral immunity.